Showing 1231-1240 of 1614 results for "".
- Ivantis Announces Results of Comparative MIGS Clinical Trialhttps://modernod.com/news/ivantis-announces-results-of-comparative-migs-clinical-trial/2480238/Ivantis, developer of the Hydrus Microstent, announced the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS). Results from the study will be presented by David Chang, MD, clinical professor of Ophthalmology at the University of California, San Francisco, during
- SERI Lugano: ParaCel Riboflavin Selected by FDA for Epi-on Cross-Linking for Keratoconushttps://modernod.com/news/seri-lugano-paracel-riboflavin-selected-by-fda-for-epi-on-cross-linking-for-keratoconus/2480255/The Switzerland Eye Research Institute has announced that the breakthrough transepithelial riboflavin formulation known as ParaCel, and based on the research of its CEO and Founder Roberto Pinelli, MD, has been selected among many others by the FDA for an epithelium-on corneal collagen cross-link
- Bio-Tissue to Present Webinar in 3-D Showcasing New Treatment Regimen to Diagnose and Treat Mechanical Dry Eyehttps://modernod.com/news/bio-tissue-to-present-webinar-in-3-d-showcasing-new-treatment-regimen-to-diagnose-and-treat-mechanical-dry-eye/2479188/Bio-Tissue announced today that it will present a special 3-D webinar on Wednesday, May 19, 2021, from 8:30 pm to 9:30 pm EDT, hosted by Neel Desai, MD, who will demonstrate his novel surgical technique known as Reservoir Restoration to treat Mechanical Dry Eye (MDE). He will also discuss how to
- Heidelberg and NetraMind Collaborate to Deliver AI-Powered Choroid Analysis on AppWay Marketplacehttps://modernod.com/news/heidelberg-and-netramind-collaborate-to-deliver-ai-powered-choroid-analysis-on-appway-marketplace/2484166/Heidelberg Engineering announced a new collaboration with NetraMind Innovations, an AI-driven image analysis software company founded by retinal specialists and machine learning engineers. Their new application, NMI-ChoroidAI,* is now available via the Heidelb
- Brent Saunders: Bausch + Lomb to Return enVista IOLs to Market Following Voluntary Recallhttps://modernod.com/news/bausch-lomb-returning-envista-iols-to-market-following-voluntary-recall/2482752/Bausch + Lomb announced it has identified the event that led to its recent
- Biocon Biologics Secures Market Entry Date for Yesafili, Interchangeable Biosimilar to Eylea in the UShttps://modernod.com/news/biocon-biologics-secures-market-entry-date-for-yesafili-interchangeable-biosimilar-to-eylea-in-the-us/2482736/Biocon Biologics announced a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in the United States. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is used to tre
- Harrow Secures Medicare Part D Market Access for Vevyehttps://modernod.com/news/harrow-secures-medicare-part-d-market-access-for-vevye/2482535/Harrow announced that beginning January 1, 2025, Harrow’s dry eye disease treatment, Vevye, will be included in the formularies of major plan sponsors, including Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. Collectively, these plan sponsors provide coverage for more tha
- Microsurgical Technology (MST) Announces Global Partnership with Vista Ophthalmicshttps://modernod.com/news/microsurgical-technology-mst-announces-global-partnership-with-vista-ophthalmics/2482446/Microsurgical Technology (MST) announced an exclusive global partnership with ophthalmic device company Vista Ophthalmics that will introduce Vista Ophthalmics' products—Vista 1-Step and Vista IS—to the global market. Financial terms of the deal were not disclosed.
- FDA Grants Notal Vision Home OCT System De Novo Marketing Authorizationhttps://modernod.com/news/fda-grants-notal-vision-home-oct-scanly-de-novo-marketing-authorization/2482282/Notal Vision announced that the FDA has granted De Novo authorization for its patient self-operated Scanly Home OCT device. Designated by the FDA as a breakthrough device for patients suffering from wet age-related macular degeneration (AMD), Scanly Home OCT aims to improve persona
- Harrow Partners with Healthcare Market Access Technology Platforms to Support Launch of Vevyehttps://modernod.com/news/harrow-partners-with-healthcare-market-access-technology-platforms-to-support-launch-of-vevye/2482037/Harrow announced that it has partnered with three healthcare technology platforms to expand US availability of dry eye drug Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) ophthalmic solution based on a water-free semifluorinated alkane (